Non-muscle Invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Non-muscle Invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]
A Phase 1 trial of intravesical Enfortumab Vedotin for non-muscle invasive bladder cancer was terminated, with the study status updated acco…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection [Phase 3]
A Phase 3 clinical trial evaluating blue light resection for high-risk non-muscle invasive bladder cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
A clinical trial update notes mood alterations in patients with non-muscle invasive bladder cancer treated with intravesical BCG. The study …
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Results from the CISTO trial compare intravesical therapy with surgical options as treatments for bladder cancer. The study includes non-mus…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Clinical trial INSITE investigates pre-surgical identification of muscle-invasive tumor involvement in patients with urothelial carcinoma sc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) [Phase 3]
This document announces the recruitment for a Phase 3 clinical trial comparing standard treatments in people with non-muscle invasive bladde…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer [Phase 2, Phase 3]
A multicenter Phase 2/3 clinical trial evaluating intravesical Bacillus Calmette-Guerin in combination with ALT-803 (N-803) for BCG-unrespon…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer [Phase 2]
This document reports a Phase 2 clinical trial evaluating Ablation Therapy for intermediate-risk non-muscle invasive bladder cancer. The stu…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC [Phase 3]
Phase 3 trial update for DV in combination with Bacillus Calmette-Guérin in HER2-expressing, BCG-naïve high-risk non-muscle invasive bladder…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors [Phase 2]
This document provides an update on the Phase 2 trial of pemigatinib in non-muscle invasive bladder cancer patients with recurrent low- or i…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer [Phase 4]
Phase 4 clinical trial comparing chemoablation or bladder resection with adjuvant chemotherapy for recurrent non-muscle invasive bladder can…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial [Phase 2, Phase 3]
A randomized Phase 2/3 trial is evaluating submucosal gemcitabine injections to prevent recurrence in patients with intermediate- and high-r…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study [Phase 2]
This update describes an open-label, randomized Phase 2 trial evaluating toripalimab with or without sequential intravesical gemcitabine-mit…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer [NA]
A clinical trial evaluating whether urine tumor DNA can be used to de-intensify surveillance in patients with non-muscle invasive bladder ca…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy [Phase 1]
Phase 1 trial to assess the safety and tolerability of RAG-01 in patients with non-muscle-invasive bladder cancer unresponsive to BCG therap…
-
FDA approval · 2025-09-09FDA Approved: INLEXZO — Original Application (Janssen Biotech, Inc)
FDA approved INLEXZO, gemcitabine delivered intravesically, under Janssen’s original NDA for bladder cancer.
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment [Phase 1]
This is an early-phase (Phase 1) clinical trial evaluating the investigational drug 2141-V11 in patients with non-muscle invasive bladder ca…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: A Phase I Intravesical PPM Therapy for NMIBC [Phase 1]
This update announces a Phase I intravesical PPM therapy for non-muscle-invasive bladder cancer that is currently recruiting. It represents …
-
CLINICAL_TRIALS research · 2025-08-28Clinical Trial Update: Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 3]
Phase 3 study evaluating FE 999326 administered intravesically in Japanese patients with high-grade, BCG-unresponsive non-muscle invasive bl…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer [Phase 1]
A Phase 1/1b study of ZH9 for non-muscle invasive bladder cancer is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
A clinical trial update about an AI-based prediction tool being studied for non-muscle-invasive bladder cancer; the study is currently recru…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer [Phase 1, Phase 2]
This clinical trial update describes an ongoing Phase 1/Phase 2 study evaluating intravesical FL115 alone or in combination with BCG for non…
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC [NA]
Ongoing clinical trial evaluating whether adding pelvic lymph node dissection during radical cystectomy affects prognosis in patients with h…
-
CLINICAL_TRIALS research · 2025-08-03Clinical Trial Update: RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients [Phase 2]
A Phase 2 trial is evaluating RC48 in combination with radiotherapy for HER2-expressing high-risk non-muscle invasive bladder cancer patient…
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) [Phase 2]
This is a Phase 2 trial comparing Balversa (erdafitinib) to investigator-choice intravesical chemotherapy in patients with high-risk non-mus…